Below median levels of BIRC5 were associated with elevated relapse rates in AML patients in adjusted analyses HR 0.54 (0.38–0.76) p = 0.0005 but this was not observed maintained when the CBF group of AML patients were analysed alone HR 0.37 (0.09–1.49) p = 0.15. This evidence concerns the gene CEBPZ and acute myeloid leukemia.